Zestoretic: Advanced Dual-Therapy Hypertension Control
| Product dosage: 17.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.48 | $44.28 (0%) | 🛒 Add to cart |
| 60 | $1.17 | $88.56 $70.45 (20%) | 🛒 Add to cart |
| 90 | $1.07 | $132.84 $96.61 (27%) | 🛒 Add to cart |
| 120 | $1.01 | $177.13 $121.77 (31%) | 🛒 Add to cart |
| 180 | $0.96 | $265.69 $173.10 (35%) | 🛒 Add to cart |
| 270 | $0.93 | $398.53 $250.59 (37%) | 🛒 Add to cart |
| 360 | $0.91
Best per pill | $531.38 $328.08 (38%) | 🛒 Add to cart |
Synonyms | |||
Zestoretic represents a cornerstone in modern antihypertensive therapy, combining two established pharmacological agents into a single, convenient tablet. This fixed-dose combination product contains lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. It is specifically formulated for patients whose blood pressure is not adequately controlled on monotherapy, providing clinicians with a powerful tool for achieving target blood pressure goals. The synergistic action of these components targets multiple physiological pathways involved in blood pressure regulation, offering enhanced efficacy compared to either component alone.
Features
- Contains lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) in fixed-dose combinations
- Available in multiple strength options: 10/12.5 mg, 20/12.5 mg, and 20/25 mg (lisinopril/hydrochlorothiazide)
- Once-daily dosing regimen for improved adherence
- Standardized formulation ensuring consistent drug delivery
- Bioequivalent to individual components administered concurrently
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Provides superior blood pressure reduction compared to monotherapy through complementary mechanisms of action
- Reduces pill burden through fixed-dose combination, enhancing medication adherence
- Offers convenient once-daily dosing that supports long-term treatment persistence
- Demonstrates proven efficacy across diverse patient populations with hypertension
- May reduce cardiovascular morbidity and mortality through effective blood pressure control
- Provides cost-effective treatment option compared to separate prescriptions
Common use
Zestoretic is primarily indicated for the treatment of hypertension in patients for whom combination therapy is appropriate. This typically includes patients whose blood pressure remains uncontrolled on either lisinopril or hydrochlorothiazide monotherapy, or those who require multiple antihypertensive agents to achieve target blood pressure levels. The medication may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals, particularly those with stage 2 hypertension or above. Clinical decision-making should consider individual patient characteristics, including race, age, and comorbid conditions.
Dosage and direction
The dosage of Zestoretic should be individualized based on patient response and tolerability. Therapy should typically begin after unsuccessful monotherapy with either component. The usual recommended starting dose is one Zestoretic 10/12.5 tablet once daily. Dosage may be titrated upward after 2-3 weeks of therapy based on blood pressure response. The maximum recommended daily dose is 80 mg lisinopril and 50 mg hydrochlorothiazide. Administration should occur at approximately the same time each day, with or without food. Tablet should be swallowed whole with a glass of water; it should not be crushed or chewed.
Precautions
Patients should be monitored for hypotension, especially during initial dose titration and in volume-depleted patients. Renal function should be assessed before and during treatment, particularly in patients with renal impairment, heart failure, or collagen vascular disease. Serum electrolytes, particularly potassium, sodium, and magnesium, should be monitored regularly due to the potential for hydrochlorothiazide-induced electrolyte disturbances. Caution is advised in patients with impaired hepatic function or progressive liver disease, as minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Patients should be advised to avoid excessive perspiration and dehydration which may lead to excessive blood pressure reduction.
Contraindications
Zestoretic is contraindicated in patients with known hypersensitivity to any component of this product or other sulfonamide-derived drugs. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy and in patients with hereditary or idiopathic angioedema. The medication is contraindicated in patients with anuria and in those who are hypersensitive to other ACE inhibitors. Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes mellitus. The medication is contraindicated during pregnancy due to potential fetal harm.
Possible side effect
Common adverse reactions may include dizziness (6.5%), headache (5.2%), cough (3.9%), fatigue (3.0%), and orthostatic effects (1.9%). Less frequent side effects may include gastrointestinal disturbances, impotence, rash, and photosensitivity. Serious adverse reactions may include angioedema, which requires immediate medical attention, particularly if involving the tongue, glottis, or larynx. Other potentially serious side effects include hypotension in volume-depleted patients, impaired renal function, hyperkalemia, hyponatremia, hypomagnesemia, and hypochloremic alkalosis. Hematologic effects including neutropenia/agranulocytosis and hemolytic anemia have been reported rarely.
Drug interaction
Zestoretic may interact with several medication classes. Concomitant use with other antihypertensive agents may potentiate blood pressure-lowering effects. Nonsteroidal anti-inflammatory drugs may reduce the antihypertensive effect and increase risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Lithium levels may increase with concomitant thiazide use. The hypoglycemic effect of insulin and oral antidiabetic agents may be enhanced. Colesevelam and cholestyramine may reduce absorption of hydrochlorothiazide. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is near the time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistency in dosing is important for maintaining stable blood pressure control, but occasional missed doses are unlikely to significantly impact long-term blood pressure management. Patients should be educated on the importance of adherence and provided with strategies to incorporate medication into daily routines.
Overdose
Overdose may manifest as hypotension, which could be severe, electrolyte disturbances, dehydration, and renal impairment. Lisinopril overdose may cause hypotension, while hydrochlorothiazide overdose may lead to electrolyte depletion. Management should include supportive measures with aggressive fluid replacement for volume depletion. Gastric lavage may be considered if ingestion was recent. Hemodialysis may be effective for removing both components, particularly lisinopril. Serum electrolytes and creatinine should be monitored, and appropriate corrective measures implemented. Vasopressors may be required for management of profound hypotension.
Storage
Zestoretic tablets should be stored at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication should be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets or other areas subject to high humidity. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient circumstances. Patients should consult their healthcare provider for personalized medical advice and before making any changes to their treatment regimen. The complete prescribing information should be consulted for comprehensive details regarding use, warnings, and precautions.
Reviews
Clinical studies have demonstrated that Zestoretic provides effective blood pressure control in a significant majority of patients who have responded inadequately to monotherapy. In controlled trials, the combination produced greater blood pressure reduction than either component alone, with mean reductions of 20-25 mmHg systolic and 10-15 mmHg diastolic. Long-term extension studies have shown maintained efficacy over 12-24 months of treatment. Patient satisfaction surveys indicate high acceptance of the fixed-dose combination due to convenience and reduced pill burden. Healthcare providers report improved adherence rates and better achievement of blood pressure goals with combination therapy compared to free combinations of the individual components.